Advertisement

Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty

  • Mara A. G. HollanderEmail author
  • Julie M. Donohue
  • Bradley D. Stein
  • Elizabeth E. Krans
  • Marian P. Jarlenski
Original Research

Abstract

Background

The association between pharmaceutical industry promotion and physician opioid prescribing is poorly understood. Whether the influence of industry gifts on prescribing varies by specialty is unknown.

Objective

To examine the relationship between opioid-related gifts to physicians and opioid prescribing in the subsequent year across 7 physician specialties.

Design

Panel study using data from 2014 to 2016.

Participants

236,103 unique Medicare Part D physicians (389,622 physician-years) who received any gifts from pharmaceutical companies measured using Open Payments and prescribed opioids in the subsequent year.

Main Measures

Amounts paid by pharmaceutical companies for opioid-related gifts including meals and lodging; quartile of opioid prescribing as a percent of total prescribing compared with other same-specialty physicians.

Key Results

In 2014–2015, 14.1% of physician received opioid-related gifts from the industry with 2.6% receiving > $100. Gifts varied by specialty and were concentrated among two pharmaceutical companies responsible for 60% of the value of opioid-related gifts. Receiving opioid-related gifts was associated with greater prescribing of opioids compared with same-specialty physicians in the next year. Primary care physicians are nearly 3.5 times as likely to be in the highest quartile of prescribing versus the lower quartiles if they were paid ≥ $100. Psychiatrists and neurologists were 7 to 13 times as likely to be in a higher quartile of opioid prescribing compared with colleagues who were paid $0 in the preceding year.

Conclusions

The value of opioid-related gifts given to physicians varies substantially by provider specialty, as does the relationship between payment amounts and prescriber behavior in the following year.

KEY WORDS

opioids prescribing gifts 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Supplementary material

11606_2019_5470_MOESM1_ESM.docx (69 kb)
ESM 1 (DOCX 68.9 kb)

References

  1. 1.
    2017. Centers for Disease Control Prescription Opioid Data. Accessed at Centers for Disease Control at https://www.cdc.gov/drugoverdose/data/prescribing.html
  2. 2.
    Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016;315(15):1624-45.CrossRefGoogle Scholar
  3. 3.
    Hadland SE, Cerda M, Li Y, Krieger MS, Marshall BDL. Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing. JAMA Intern Med 2018;178(6):861-3.CrossRefGoogle Scholar
  4. 4.
    Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerda M. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses. JAMA Netw Open 2019;2(1):e186007.CrossRefGoogle Scholar
  5. 5.
    Hadland SE, Krieger MS, Marshall BDL. Industry Payments to Physicians for Opioid Products, 2013-2015. Am J Public Health 2017;107(9):1493-5.CrossRefGoogle Scholar
  6. 6.
    Gibbons RV, Landry FJ, Blouch DL, Jones DL, Williams FK, Lucey CR, et al. A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998;13(3):151-4.CrossRefGoogle Scholar
  7. 7.
    Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996;5(4):201-6.CrossRefGoogle Scholar
  8. 8.
    Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290(2):252-5.CrossRefGoogle Scholar
  9. 9.
    Babcock L, Loewenstein G, Issacharoff S. Creating Convergence: Debiasing Biased Litigants. Law Soc Inq 1997;22(4):913-25.CrossRefGoogle Scholar
  10. 10.
    Emanuel G, Thomas K. Top Executives of Insys, an Opioid Company, Are Found Guilty of Racketeering. The New York Times. New York.Google Scholar
  11. 11.
    Dolmetsch C. Purdue’s Sackler Family Must Face Opioid Suits in New York. Bloomberg. New York.Google Scholar
  12. 12.
    Hoffman J. Purdue Pharma and Sacklers Reach $270 Million Settlement in Opioid Lawsuit. The New York Times, New York.Google Scholar
  13. 13.
    Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations. Company Admits Illegal Conduct Regarding Promotion of Subsys, a Powerful Opioid Painkiller. 19-621 ed: Department of Justice Office of Public Affairs; 2019.Google Scholar
  14. 14.
    Magnus SA. Physicians’ financial incentives in five dimensions: a conceptual framework for HMO managers. Health Care Manag Rev 1999;24(1):57-72.Google Scholar
  15. 15.
    Levy B, Paulozzi L, Mack KA, Jones CM. Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012 Am J Prev Med 2015;49(3):409-13.CrossRefGoogle Scholar
  16. 16.
    Centers for Medicare & Medicaid Services. Medicare Provider Utilization and Payment Data: Part D Prescriber Summary table, CY2015. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2015.html.
  17. 17.
    Centers for Medicare & Medicaid Services. Medicare Provider Utilization and Payment Data: Part D Prescriber Summary table, CY2016. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2016.html.
  18. 18.
    Centers for Medicare & Medicaid Services. Medicare Provider Utilization and Payment Data: Part D Drug National Summary table, CY2015. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2015.html.
  19. 19.
    Centers for Medicare & Medicaid Services. Medicare Provider Utilization and Payment Data: Part D Drug National Summary table, CY2016. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2016.html.
  20. 20.
    Opioids: Brand names, generic names & street names. It Matters Colorado.Google Scholar
  21. 21.
    Centers for Medicare & Medicaid Services. Medicare Provider Utilization and Payment Data: Part D Prescriber PUF NPI Drug table, CY2015. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2015.html.
  22. 22.
    Centers for Medicare & Medicaid Services. Medicare Provider Utilization and Payment Data: Part D Prescriber PUF NPI Drug table, CY2016. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2016.html.
  23. 23.
    Centers for Medicare & Medicaid Services. Complete 2014 Program Year Open Payments Dataset. https://www.cms.gov/OpenPayments/Explore-the-Data/Dataset-Downloads.html.
  24. 24.
    Centers for Medicare & Medicaid Services. Complete 2015 Program Year Open Payments Dataset. https://www.cms.gov/OpenPayments/Explore-the-Data/Dataset-Downloads.html.
  25. 25.
    Tigas M, Jones RG, Ornstein C, Groeger L. Dollars for Docs NPI/Open Payments Crosswalk.Google Scholar
  26. 26.
    Jones RG, Ornstein C. Matching Industry Payments to Medicare Prescribing Patterns: An Analysis. ProPublica, Manhattan; 2016.Google Scholar
  27. 27.
    DeJong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. JAMA Intern Med 2016;176(8):1114-22.CrossRefGoogle Scholar
  28. 28.
    PhRMA. Code on Interactions with Healthcare Professionals. 2008.Google Scholar
  29. 29.
    Williams R. Generalized ordered logit/partial proportional odds models for ordinal dependent variables. Stata J 2006;6(1):58-82.CrossRefGoogle Scholar
  30. 30.
    Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt 2014;34(5):502-8.CrossRefGoogle Scholar
  31. 31.
    2018. McCausland P, Connor T OxyContin maker Purdue to stop promoting opioids in light of epidemic. Accessed at NBC News at https://www.nbcnews.com/storyline/americas-heroin-epidemic/oxycontin-maker-purdue-stop-promoting-opioids-light-epidemic-n846726 on March 18, 2019.
  32. 32.
    Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354.Google Scholar
  33. 33.
    Lo B, Grady D. Payments to Physicians: Does the Amount of Money Make a Difference? JAMA. 2017;317(17).CrossRefGoogle Scholar
  34. 34.
    Wood SF, Podrasky J, McMonagle MA, Raveendran J, Bysshe T, Hogenmiller A, et al. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia. PLoS One 2017;12(10):e0186060.CrossRefGoogle Scholar
  35. 35.
    Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. JAMA Intern Med 2016;176(6):763-8.CrossRefGoogle Scholar
  36. 36.
    Dufour R, Joshi AV, Pasquale MK, Schaaf D, Mardekian J, Andrews GA, et al. The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. Pain Pract 2014;14(3):E106-15.CrossRefGoogle Scholar
  37. 37.
    Anderson KK, Hendrick F, McClair V. National Trends in High-dose Chronic Opioid Utilization among Dually Eligible and Medicare-only Beneficiaries (2006-2015). Data Analysis Brief: Center for Medicare and Medicaid Services; 2018.Google Scholar
  38. 38.
    Meara E, Horwitz JR, Powell W, McClelland L, Zhou W, O’Malley AJ, et al. State Legal Restrictions and Prescription-Opioid Use among Disabled Adults. N Engl J Med 2016;375(1):44-53.CrossRefGoogle Scholar
  39. 39.
    Carey CM, Jena AB, Barnett ML. Patterns of Potential Opioid Misuse and Subsequent Adverse Outcomes in Medicare, 2008 to 2012. Ann Intern Med 2018;168(12):837-45.CrossRefGoogle Scholar
  40. 40.
    Boccuti C, Swoope C, Damico A, Neuman T. Medicare Patients’ Access to Physicians: A Synthesis of the Evidence. Kaiser Family Foundation, San Francisco; 2013.Google Scholar
  41. 41.
    Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to Physicians in 2015. JAMA. 2017;317(17):1774-84.CrossRefGoogle Scholar
  42. 42.
    Cialdini RB. Influence: The Psychology of Persuasion: Harper Business; 1993.Google Scholar
  43. 43.
    Katz D, Caplan AL, Merz JF. All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift Giving. Am J Bioeth 2003;3(3):39-46.CrossRefGoogle Scholar
  44. 44.
    Manchanda P, Xie Y, Youn N. The Role of Targeted Communication and Contagion in Product Adoption. Mark Sci 2008;27(6):961-76.CrossRefGoogle Scholar
  45. 45.
    Commercial Access to Physicians: Medical Industry Sales Reps Accessibility to U.S. Physicians. Irvine, CA: SK&A; 2017.Google Scholar
  46. 46.
    Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, et al. Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing. JAMA. 2017;317(17):1785-95.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  1. 1.Department of Health Policy and ManagementUniversity of PittsburghPittsburghUSA
  2. 2.RAND CorporationPittsburghUSA
  3. 3.Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Womens Research InstituteUniversity of PittsburghPittsburghUSA

Personalised recommendations